Taking aim at human papillomavirus (HPV)16-induced cervical lesions in a phase I/IIa study with its therapeutic cancer vaccine, Norway-based Vaccibody AS added NOK220 million (US$25 million) to the coffers in a private placement, selling 880,000 shares at NOK250 each.